Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Janet Pavese"'
Autor:
Li Xu, Ryan Gordon, Rebecca Farmer, Abhinandan Pattanayak, Andrew Binkowski, Xiaoke Huang, Michael Avram, Sankar Krishna, Eric Voll, Janet Pavese, Juan Chavez, James Bruce, Andrew Mazar, Antoinette Nibbs, Wayne Anderson, Lin Li, Borko Jovanovic, Sean Pruell, Matias Valsecchi, Giulio Francia, Rick Betori, Karl Scheidt, Raymond Bergan
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)
In this study, the authors identify and validate a halogen-substituted isoflavanone able to inhibit prostate cancer cell motility, invasion and metastasis in vitro and in vivo. They demonstrate its ability to selectively inhibit activation of client
Externí odkaz:
https://doaj.org/article/bfb4cee65d69447bbe13390df2a07b87
Autor:
Diarmuid Martin Moran, Abraham Guerrero, Yoko Ueno, Jung Wook Park, Janet Pavese, Yuichiro Kaneko, Maria Matsangou, Kohei Shitara
Publikováno v:
Journal of Clinical Oncology. 41:466-466
466 Background: CLDN18.2, a targetable biomarker, is a tight junction protein normally confined to gastric mucosa of healthy tissue and often retained in G/GEJa. Zolbetuximab, a chimeric IgG1 monoclonal antibody, binds to CLDN18.2 and mediates cancer
Autor:
Amit Desai, Keun-Wook Lee, Tomasz Wojtkowski, Yoko Ueno, Jung Wook Park, Yung-Jue Bang, Kohei Shitara, Fotios Loupakis, Janet Pavese, Jianning Yang, Akihiro Yamada, Samuel J. Klempner
Publikováno v:
Journal of Clinical Oncology. 39:e16078-e16078
e16078 Background: Zolbetuximab is a chimeric IgG1 monoclonal antibody that targets Claudin 18.2 (CLDN18.2), a tight junction protein that is normally confined to gastric mucosa but is retained in G/GEJ. A phase 2 (NCT01630083, FAST) trial demonstrat